A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.

Trial Profile

A Phase 3, Three-Arm, Randomized, Open-Label Study of Interferon Alfa Alone, CCI-779 Alone, and the Combination of Interferon Alfa and CCI-779 in First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Interferon alpha-2a (Primary) ; Temsirolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 07 Mar 2010 Results from a quality-adjusted survival analysis presented at the 2010 Genitourinary Cancers Symposium
    • 05 Mar 2010 Results of an analysis of serum LDH as a predictive biomarker for mTOR inhibition in patients with mRCC were presented at ASCO 2010 Genitourinary Cancers Symposium.
    • 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2003-0924).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top